Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why These Dow "Dogs" Are Soaring in 2014

The Dogs of the Dow strategy has many fans in the investing world. And there are some good reasons for that popularity. For one, by focusing on a single financial metric -- dividend yield -- it is one of the easiest stock plans to apply. And it can't hurt that the strategy often beats the market: Last year it trounced the Dow Jones Industrial Average (DJINDICES: ^DJI  ) by 8 percentage points.

The Dogs of the Dow strategy is as simple as it gets: Buy the index members that boast the highest dividend yields. Because high yields tend to correlate with lower stock prices, you should be rewarded over time by owning a basket of blue chips that were closer to the bottom of their business cycles than to the top, and are primed for a rebound. At the very least, investors collect market-thumping dividend income by using this strategy. The average yield of the 10 Dow dogs for 2014 was 3.6% -- about 1 percentage point above what you could get from 10-year Treasury bonds.

With that in mind, let's look at the two Dow dogs that have posted the biggest stock-price gains so far in 2014: Intel (NASDAQ: INTC  ) and Merck (NYSE: MRK  ) .

The undead PC
Up 20% through June, Intel is the Dow's second-best performer year to date.

INTC Chart

INTC data by YCharts.

That 17-percentage-point lead over the market owes to a turnaround in the tech giant's business. The past few years have been rough for Intel, with sales and profits slipping as PC sales volumes and prices both fell. But things look a lot brighter for the chipmaker these days: Thanks to a rebound in business PC sales, Intel last month boosted its revenue and profitability outlook for the year. The company now expects both of those figures to improve for the first time since 2010. Consequently, Intel's story looks like a textbook example of how the Dogs of the Dow strategy can work for investors: Its business really was near a turning point as the company's dividend yield marched toward 4%. 


A streamlined drugmaker
Merck is the Dow's third-biggest winner in 2014, posting an 18% jump year to date. But the stock's gain isn't due to any big turnaround in the drugmaker's business. In fact, last quarter Merck posted another 4% drop in sales. And yet the stock continues to rise as investors applaud the company's cost cuts and increasing cash returns to shareholders. Merck is in the middle of a huge restructuring program that has already sliced 3,000 positions from its workforce, with about 5,000 left to go. The financial benefits of that move and other reductions are already showing up in Merck's bottom line. For example, administrative expenses fell by 8% last quarter, or double the pace that revenue shrank. 

Merck also took a huge step toward streamlining its business when it announced in May that it would sell off its consumer care portfolio. The sale means that Merck loses popular brands including Afrin, Coppertone, and Claritin, but gains a leaner operation with more focus on core pharmaceutical products that have the largest long-term potential. Meanwhile, investors have to like that Merck will net $9 billion in cash from the deal, which it can use to fund further payout hikes and share repurchases.

Foolish final thoughts
Investors who bought Intel and Merck for their outsized dividends have enjoyed a bonus in the form of solid share-price gains in 2014. Of course, that doesn't mean the Dogs of the Dow strategy will work out so well in all, or even most, cases. Still, for investors seeking above-average dividend income and a decent shot at capital appreciation, the highest-yielding members of the Dow can be a great place to start your search.

More top dividend picks
The smartest investors know that dividend stocks like Merck and Intel simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3019953, ~/Articles/ArticleHandler.aspx, 9/3/2015 11:31:01 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Demitrios Kalogeropoulos

Demitrios covers consumer goods and media companies for, as well as broader moves in the economy.

Today's Market

updated Moments ago Sponsored by:
DOW 16,518.24 166.86 1.02%
S&P 500 1,970.24 21.38 1.10%
NASD 4,792.67 42.69 0.90%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/3/2015 11:15 AM
^DJI $16512.99 Up +161.61 +0.99%
INTC $29.36 Up +0.76 +2.66%
Intel CAPS Rating: ****
MRK $53.44 Up +0.46 +0.87%
Merck & Co., Inc. CAPS Rating: ****